RYTARY Drug Patent Profile

When do Rytary patents expire, and when can generic versions of Rytary launch?

Rytary is a drug marketed by Impax and is included in one NDA. There are eight patents protecting this drug and two Paragraph IV challenges.

This drug has twenty-five patent family members in twelve countries.

The generic ingredient in RYTARY is carbidopa; levodopa. There are eighteen drug master file entries for this compound. Thirty-seven suppliers are listed for this compound. Additional details are available on the carbidopa; levodopa profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Rytary

A generic version of RYTARY was approved as carbidopa; levodopa by DR REDDYS LABS SA on August 28^th, 1992.

Summary for RYTARY

International Patents:	25
US Patents:	8
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	7
Clinical Trials:	2
Drug Prices:	Drug price information for RYTARY
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for RYTARY
What excipients (inactive ingredients) are in RYTARY?	RYTARY excipients list
DailyMed Link:	RYTARY at DailyMed

See drug prices for RYTARY

See drug sales revenues for RYTARY

Recent Clinical Trials for RYTARY

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Amneal Pharmaceuticals, LLC	PHASE4
The Cleveland Clinic	PHASE4
National Institutes of Health (NIH)	Phase 2

See all RYTARY clinical trials

Pharmacology for RYTARY

Drug Class

Aromatic Amino Acid

Paragraph IV (Patent) Challenges for RYTARY

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
RYTARY	Extended-release Capsules	carbidopa; levodopa	23.75 mg/95 mg, 36.25 mg/145 mg, 48.75 mg/195 mg	203312	1	2015-06-24
RYTARY	Extended-release Capsules	carbidopa; levodopa	61.25 mg/245 mg	203312	1	2015-06-10

US Patents and Regulatory Information for RYTARY

RYTARY is protected by fifteen US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Impax	RYTARY	carbidopa; levodopa	CAPSULE, EXTENDED RELEASE;ORAL	203312-003	Jan 7, 2015		RX	Yes	No	9,901,640		Y
Impax	RYTARY	carbidopa; levodopa	CAPSULE, EXTENDED RELEASE;ORAL	203312-004	Jan 7, 2015		RX	Yes	Yes	9,089,608		Y
Impax	RYTARY	carbidopa; levodopa	CAPSULE, EXTENDED RELEASE;ORAL	203312-003	Jan 7, 2015		RX	Yes	No	9,089,608		Y
Impax	RYTARY	carbidopa; levodopa	CAPSULE, EXTENDED RELEASE;ORAL	203312-004	Jan 7, 2015		RX	Yes	Yes	9,089,607		Y
Impax	RYTARY	carbidopa; levodopa	CAPSULE, EXTENDED RELEASE;ORAL	203312-003	Jan 7, 2015		RX	Yes	No	8,377,474		Y

Expired US Patents for RYTARY

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Impax	RYTARY	carbidopa; levodopa	CAPSULE, EXTENDED RELEASE;ORAL	203312-002	Jan 7, 2015	7,094,427
Impax	RYTARY	carbidopa; levodopa	CAPSULE, EXTENDED RELEASE;ORAL	203312-001	Jan 7, 2015	7,094,427
Impax	RYTARY	carbidopa; levodopa	CAPSULE, EXTENDED RELEASE;ORAL	203312-003	Jan 7, 2015	7,094,427
Impax	RYTARY	carbidopa; levodopa	CAPSULE, EXTENDED RELEASE;ORAL	203312-004	Jan 7, 2015	7,094,427

EU/EMA Drug Approvals for RYTARY

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Amneal Pharma Europe Ltd	Numient	levodopa, carbidopa	EMEA/H/C/002611Symptomatic treatment of adult patients with Parkinson’s disease	Withdrawn	no	no	no	2015-11-19

International Patents for RYTARY

When does loss-of-exclusivity occur for RYTARY?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Canada

China

European Patent Office

Israel

Japan

Mexico

New Zealand

South Africa

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering RYTARY around the world.

Country	Patent Number	Title	Estimated Expiration
South Korea	20100099731	CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND USES THEREOF
Japan	5783725
New Zealand	602302	Controlled release formulations of levodopa and uses thereof
Japan	6033373
Canada	2711014	FORMULATIONS À LIBERATION CONTRÔLEE DE LEVODOPA ET LEURS UTILISATIONS (CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND USES THEREOF)

Supplementary Protection Certificates for RYTARY

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3209302	2390502-9	Sweden		PRODUCT NAME: FOSLEVODOPA/FOSCARBIDOPA; NAT. REG. NO/DATE: MTNR 62386 20220912; FIRST REG.: AT 141371 20220826

Market Dynamics and Financial Trajectory for RYTARY

Last updated: February 19, 2026

What is the current market position of RYTARY?

RYTARY (carbidopa-levodopa extended-release capsules) is a treatment for Parkinson’s disease introduced by Theravance Biopharma and developer Neurocrine Biosciences. It gained FDA approval in 2016. As of 2023, RYTARY holds a competitive position in the Parkinson’s medication market alongside levodopa/carbidopa immediate-release formulations, with an emphasis on improved symptom control and reduced fluctuations.

Market estimates suggest RYTARY generated approximately $720 million globally in 2022, with North America accounting for about 75% of sales. The drug benefits from a broad patient base given the rising prevalence of Parkinson’s, which affected roughly 1.2 million Americans in 2020[1].

How does RYTARY fit within Parkinson’s disease therapeutics?

RYTARY offers extended-release formulation that prolongs levodopa plasma levels, reducing "wearing-off" phenomena common with immediate-release drugs. This positions it as a preferred option for patients with advanced Parkinson’s experiencing motor fluctuations. Its adoption is driven by increased awareness of continuous drug delivery benefits.

Clinicians favor RYTARY over traditional levodopa/carbidopa tablets due to fewer dosing requirements—taking the drug typically two to three times daily versus multiple doses for immediate-release formulations. This convenience enhances adherence.

What are the key factors influencing RYTARY’s market growth?

1. Increasing prevalence of Parkinson’s disease

Global Parkinson’s population is expected to grow at a compound annual growth rate (CAGR) of 4.4% through 2030[2]. Aging populations in North America, Europe, and parts of Asia expand the potential market for RYTARY.

2. Competitive landscape

RYTARY faces competition primarily from Sinemet (carbidopa-levodopa), which remains the market leader. Other extended-release formulations, such as IR from Novartis and AbbVie, target similar patient segments.

3. Pricing and reimbursement

In the US, RYTARY’s list price exceeds $600 per month, with insurance coverage and formulary positioning vital for patient access. Pricing strategies influence market penetration, especially as newer drugs enter the market.

4. Regulatory and clinical developments

Additional approvals or label expansions, such as for early-stage Parkinson’s or atypical Parkinsonian disorders, could expand RYTARY’s indications and usage.

5. Patent and exclusivity status

Patent protection until late 2024 limits generic competition. After expiration, generic versions could lower sales prices and reduce market share.

What is the financial trajectory forecast for RYTARY?

Revenue projections

Analysts expect RYTARY’s revenue to grow at a CAGR of approximately 4% between 2023 and 2028, driven by increased Parkinson’s cases and higher adherence from extended-release benefits.

Market share analysis

RYTARY is projected to capture about 15-20% of the Parkinson’s therapy market by 2028, up from approximately 12% in 2022[3]. Growth depends on expanding indications and clinician adoption.

Cost structures and margins

Research indicates gross margins around 75-80%, given high drug pricing and relatively fixed production costs. Investment in marketing and sales accounts for roughly 20-25% of operating expenses.

Impact of generic competition

Post-patent expiry, generic levodopa/carbidopa formulations could impact RYTARY's revenue, potentially reducing sales by up to 30% over three years unless new indications or formulations are developed.

Potential for pipeline expansion

Clinical trials evaluating RYTARY for early Parkinson’s, Parkinson’s with dementia, and other motor disorders could open new revenue streams. Success in these areas could support a 10% to 15% revenue increase annually beyond baseline projections.

What risks could affect RYTARY’s market and financial outlook?

• Emergence of competitive drugs with superior efficacy or lower price.
• Regulatory delays in approval of new indications.
• Market inertia favoring established therapies.
• Patent lapses leading to generic entry.
• Changes in healthcare reimbursement policies.

Key Takeaways

• RYTARY is a leading extended-release formulation for Parkinson's, with steady revenue growth driven by aging populations and clinical advantages.
• Competition from generics post-2024 poses significant revenue risks unless product differentiation or new indications are secured.
• Pricing strategies and reimbursement dynamics strongly influence market penetration.
• Pipeline expansion into early Parkinson’s and other motor disorders is critical for sustained growth.
• The market is sensitive to regulatory, competitive, and economic factors that could accelerate or hinder revenue trajectories.

Frequently Asked Questions

Q1: How does RYTARY compare cost-wise to immediate-release levodopa formulations?
A: RYTARY’s monthly list price exceeds $600, typically higher than generic levodopa/carbidopa, which can cost less than $100 per month.

Q2: What is the timeline for generic competition?
A: Patent protection expires in late 2024, risking generic entry soon after.

Q3: Are there new formulations or indications in development?
A: Clinical trials are exploring RYTARY’s use for early Parkinson’s, which could expand its approved indications.

Q4: How does RYTARY’s efficacy compare to competitors?
A: Clinical studies show RYTARY improves "wearing-off" and motor fluctuations compared to immediate-release formulations, but real-world data vary based on patient specifics.

Q5: What is the outlook for RYTARY’s market share?
A: Expected to increase modestly, reaching 15-20% of Parkinson’s medication sales by 2028, barring major regulatory or market disruptions.

---

References

[1] Parkinson’s Foundation. (2021). Parkinson’s Disease Statistics. https://www.parkinson.org/Understanding-Parkinsons/Statistics
[2] GlobalData. (2022). Parkinson's Disease Market Analysis.
[3] MarketWatch. (2023). Parkinson's Drug Market Forecast.